183 related articles for article (PubMed ID: 15780172)
1. Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality?
Akaza H
Can J Urol; 2005 Feb; 12 Suppl 1():77-80. PubMed ID: 15780172
[TBL] [Abstract][Full Text] [Related]
2. Maximal androgen blockade for advanced prostate cancer.
Klotz L
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
[TBL] [Abstract][Full Text] [Related]
3. [Usefulness and positioning of MAB therapy for prostate cancer].
Akaza H; Chodak GW; Hirao Y
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758
[TBL] [Abstract][Full Text] [Related]
4. [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].
Matveev BP; Bukharkin BV
Vopr Onkol; 1998; 44(5):537-40. PubMed ID: 9884710
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer chemotherapy: emerging from the shadows.
Roth BJ
J Clin Oncol; 2005 May; 23(15):3302-3. PubMed ID: 15738529
[No Abstract] [Full Text] [Related]
6. [A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation].
Akaza H; Labrie F; Namiki M
Gan To Kagaku Ryoho; 2007 Apr; 34(4):657-69. PubMed ID: 17431361
[TBL] [Abstract][Full Text] [Related]
7. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T
Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233
[TBL] [Abstract][Full Text] [Related]
8. Intermittent androgen deprivation therapy: conventional wisdom versus evidence.
Tombal B
Eur Urol; 2009 Jun; 55(6):1278-80. PubMed ID: 19303201
[No Abstract] [Full Text] [Related]
9. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
10. [Early versus late hormonal treatment in advanced prostate cancer].
Allepuz Losa C; Gil Martínez P; Gil Sanz MJ; Rioja Sanz LA
Actas Urol Esp; 1999; 23(7):557-64. PubMed ID: 10488608
[No Abstract] [Full Text] [Related]
11. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
12. [Castration of prostate cancer patients and cognition].
Portin R; Koskinen A; Helenius H; Nurmi M; Salminen E
Duodecim; 2005; 121(16):1784-5. PubMed ID: 16268226
[No Abstract] [Full Text] [Related]
13. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
14. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
Yoon FH; Gardner SL; Danjoux C; Morton G; Cheung P; Choo R
J Urol; 2008 Oct; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
[TBL] [Abstract][Full Text] [Related]
15. Re: Fritz H. Schröder, Karl-Heinz Kurth, Sophie D. Fossa, et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 2009;55:14-22.
Drewa T
Eur Urol; 2009 May; 55(5):e82-3. PubMed ID: 18950934
[No Abstract] [Full Text] [Related]
16. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
17. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
18. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
19. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
20. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
